Labro Marie-Therese
INSERM U 479, CHU X Bichat, Paris, France.
Curr Opin Investig Drugs. 2002 Jan;3(1):61-8.
Although the empirical use of some antibacterial agents in various inflammatory diseases has proved beneficial in the past, it is only recently that the therapeutic anti-inflammatory potential of cyclines and macrolides has received attention worldwide. Other drugs like fosfomycin and some quinolones are also contenders for this role. Owing to the complexity of the inflammatory process, which involves many redundant cellular effectors and soluble mediators, and the obscure etiopathogenesis of many inflammatory diseases (some of which may be secondary to persistent infections), the precise mechanisms underlying the therapeutic benefit of anti-inflammatory antibiotics remain to be elucidated. Structure-activity relationships are the key to developing new anti-inflammatory agents derived from antibacterial drugs.
尽管过去在各种炎症性疾病中经验性使用某些抗菌药物已证明是有益的,但直到最近,环素类和大环内酯类药物的治疗性抗炎潜力才受到全球关注。其他药物如磷霉素和一些喹诺酮类药物也在争夺这一角色。由于炎症过程的复杂性,涉及许多冗余的细胞效应器和可溶性介质,以及许多炎症性疾病的病因发病机制尚不明确(其中一些可能继发于持续感染),抗炎抗生素治疗益处的精确机制仍有待阐明。构效关系是开发源自抗菌药物的新型抗炎药物的关键。